• conjugate-head2

BIBLIOGRAPHY ON POLYSACCHARIDE AND GLYCOCONJUGATE VACCINES AS CHRONOLOGICAL MILESTONES LEADING UP TO THE DEVELOPMENT OF THE MODERN AND HIGHLY EFFICIENT BIOSYNTH’S CONJUGATION TECHNOLOGY


Purification of capsular polysaccharides from contaminant LPS

  • "The biological and physical chemical characteristics of meningococcal polysaccharide Group C prepared by two different methods of purification."

    Porro M. et al.

    J. Biol. Standard., 8: 7-13 (1980).

Vaccines based on the mutant diphtheria protein CRM197

  • "Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of C. diphtheriae and diphtheria toxoid."

    Porro M. et al.

    J. Infect. Dis., 143: 716-724 (1980).

Determination of group-specific polysaccharides in multivalent vaccines

  • "Immunoelectrophoretic characterization of the molecular weight polydispersion of polysaccharides in multivalent bacterial capsular polysaccharide vaccines."

    Porro M. et al.

    J. Biol. Stand., 11: 65-74 (1983).

Development of glycoconjugate vaccines combining the first generation of reductive amination with
ester-activated linkers

  • "Immunochemistry of Meningococcal group B oligosaccharide-protein conjugates."

    Porro M. et al.

    Medicine Tropicale, 43 : 129-132 (1983).

  • "Specific antibodies to diphtheria toxin and type 6A Pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen."

    Porro M. et al.

    Molec. Immunol., 22: 907-919 (1985).

  • "A semi-synthetic glycoconjugate antigen prepared by chemical glycosylation of pertussis toxin by a meningococcal group C oligosaccharide hapten."

    Porro M. et al.

    Develop. Biol. Standard., Karger S. Ed., Basel, Vol 61, pp 525-530 (1985).

Development of glycoconjugate vaccines with built-in multiple specificities

  • "A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for Gram-positive and Gram-negative encapsulated bacteria."

    Porro M. et al.

    Molec. Immunol., 23 (4): 385-391 (1986).

  • "Artificial glycoproteins of predetermined multivalent antigenicity as a new generation of candidate vaccines to prevent infections by encapsulated bacteria: analysis of antigenicity versus immunogenicity."

    Porro M.

    Towards better carbohydrate vaccines Edited by R.Bell and G.Torrigiani, World Health Organization pp 279-306, John Wiley & Sons Publishers (1987).

  • "Glycoproteinic conjugates having trivalent immunogenic activity"

    Porro M. et al.

    USA Patent No. 4,711,779 (1987).

Development of glycoconjugate vaccines combining the second generation of reductive amination with
ester-activated linkers

  • "Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae."

    Arndt B. and Porro M.

    Immunobiology of proteins and peptides Edited by M.Z. Atassi, Plenum Press, New York / London, Vol. VI, pg 129-148 (1991).

  • "Oligosaccharide conjugate vaccines"

    Porro M.

    USA Patent No. 5,306,492 (1994).

Development of LPS-free glycoconjugate vaccines combining the third generation of reductive amination with
ester-activated linkers to achieve optimal yield of the products in large scale production

  • "Improved Polysaccharide and Glycoconjugate Vaccines"

    Porro M.

    European Patent No. 1501542B1 (2007).

  • "Polysaccharide and Glycoconjugate Vaccines"

    Porro M.

    USA Patent No. 7,588,756 B2 (2009).

Development of broad-spectrum multi-epitopes glyconjugate vaccines with reduced amount of carrier protein

  • "Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes"

    Porro M.

    World-wide Patent Application (2013).

  • “Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria”

    Porro M.

    World-wide Patent Application (2014).